£6.0M
MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.
P
PharmEnable
PharmEnable develops next-generation small molecule drugs for challenging disease targets using an artificial intelligence platform.
£7.8MTotal raised
PharmEnable is a biotechnology company based in Cambridge that develops targeted small molecule drugs using an proprietary platform combining medicinal chemistry and artificial intelligence. The firm focuses on challenging biological targets in oncology and neurology.
Categories
Team
HS
Hannah Sore
CEO
JD
Jane Dancer
Board Chair
David Vidal
Director of Technology
David serves as chief technology officer at PharmEnable Therapeutics, following earlier R&D and cheminformatics roles at Mind the Byte, Chemotargets, and Tata Consultancy Services.
LinkedIn
Natalia Mateu
CSO
Natalia brings research and operating experience from roles at PharmEnable, the University of Cambridge, and Janssen. She previously held scientific research and postdoctoral positions following her fellowship.
LinkedInGF
Gaynor Fryers
independent NED
Jelena Aleksic
CBO
Jelena brings geneticist and entrepreneurial experience from roles including CBO at PharmEnable and director at Signalsmith Audio. She also advises businesses such as Protalea Bio and Lift Fitness Cambridge.
LinkedInKB
Keith Blundy
Investor Director
Investors
- £6.0M
- £1.8M
Funding history
£1.8M
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.